Trial Profile
A Multicenter Phase II Trial of Neoadjuvant JS001, or JS001 in Combination With Chemotherapy in Resectable NSCLC
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Mar 2024
Price :
$35
*
At a glance
- Drugs Toripalimab (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms NAJSCR
- 26 Feb 2019 Study design, arms and interventions, trial identification hs been amended.
- 26 Feb 2019 Planned End Date changed from 1 Jul 2023 to 1 Mar 2024.
- 26 Feb 2019 Planned primary completion date changed from 1 Jul 2020 to 1 Mar 2021.